Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6

Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6
复制标题

DOI:
10.1016/j.ajo.2005.03.003
复制
发表时间:
2005-08-01
影响因子:
4.2
通讯作者:
Mishima, HK
Mishima, HK
中科院分区:
医学1区
文献类型:
--
作者:
Noma, H;Funatsu, H;Mishima, HK

文献摘要

被引文献

相似文献

目的:探讨血管内皮生长因子(VEGF)与白细胞介素-6 (IL-6)的相关性是否参与视网膜分支静脉闭塞(BRVO)患者眼部黄斑水肿的发病机制。设计:回顾性病例对照研究。方法:选取19例伴有BRVO的黄斑水肿患者和7例非缺血性眼病患者作为对照组。用毛细血管非灌注面积评价视网膜缺血程度,用光学相干断层扫描检查黄斑水肿程度。玻璃体切除联合白内障手术时取房水标本,采用酶联免疫吸附法测定房水和血浆中VEGF和IL-6水平。结果:BRVO患者血清中VEGF (351 +/- 273 pg/ml)和IL-6 (7.10 +/- 6.51 pg/ml)水平较对照组(分别为119 +/- 38.7 pg/ml和2.27 +/- 1.11 pg/ml)显著升高(P= 0.0017和P= 0.0052)。VEGF与IL-6水平呈显著相关(P= 0.0396), VEGF与IL-6水平与BRVO非灌注区大小呈显著相关(P= 0.0396)
Purpose: To determine whether correlations between vascular endothelial growth factor (VEGF) or interleukin-6 (IL-6) contribute to the pathogenesis of macular edema in eyes of patients with branch retinal vein occlusion (BRVO).Design: Retrospective case-control study.Methods: Nineteen patients with macular edema with BRVO and seven patients with non,ischemic ocular disease (control group) were studied. The degree of retinal ischemia was evaluated in terms of the area of capillary non-perfusion, and the severity of macular edema was examined by optical coherence tomography. Aqueous humor samples were obtained at the time of combined vitrectomy and cataract surgery, and VEGF and IL-6 levels in aqueous humor and plasma were determined by enzyme-linked immunosorbent assay.Results: Aqueous levels of VEGF (351 +/- 273 pg/ml) and IL-6 (7.10 +/- 6.51 pg/ml) were significantly elevated in patients with BRVO compared with the control patients (119 +/- 38.7 pg/ml and 2.27 +/- 1.11 pg/ml, respectively) (P=.0017 and P=.0052, respectively). Aqueous level of VEGF was significantly correlated with that of IL-6 (P=.0396), and aqueous levels of VEGF and IL-6 were correlated with the size of the BRVO non-perfused area (P